News Biotech vTv believes small molecule GLP-1 pill can take on b... Pill could be effective in diabetes, with fewer GI effects.
News Oral insulin could still be a reality, says Novo Nordisk Last October Novo Nordisk announced that it had shelved plans to bring the world’s first oral insulin to market .
News Novo hopes data will boost new insulin in US and Germany Novo Nordisk hopes that new data supporting the cardiovascular and glycaemic safety of its Tresiba long-acting insulin will prove a game-changer in the US.
Views & Analysis ADA preview: cardio data in diabetes, drug costs and healthc... Invokana data could suggest cardio benefit for SGLT2 class.
Views & Analysis Novo Nordisk: survival of the fittest applies in diabetes an... Diabetes specialist Novo Nordisk is feeling the heat from increasingly price conscious US payers.
News Novo hopes hypoglycaemia data will boost Tresiba Lower severe hypo risk compared with Lantus - but no cardiac benefit.
News Ipsen' Bylvay fluffs its lines in biliary atresia trial Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
